April 2009
Volume 50, Issue 13
ARVO Annual Meeting Abstract  |   April 2009
Bevacizumab Intravitreal Injection for Myopic Choroidal Neovascularization
Author Affiliations & Notes
  • C. N. Romeiro
    Cornea and Cataract, Romeiro Eye Clinic, Pouso Alegre, Brazil
  • B. R. A. Nassaralla
    Cornea, Cataract and Refractive Surgery, Instituto de Olhos de Goiania, Goiania, Brazil
  • J. J. Nassaralla, Jr.
    Retina, Vitreous and Uveitis, Instituto de Olhos de Goiania and UnB, Goiania, Brazil
  • Footnotes
    Commercial Relationships  C.N. Romeiro, None; B.R.A. Nassaralla, None; J.J. Nassaralla, Jr., None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 2273. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. N. Romeiro, B. R. A. Nassaralla, J. J. Nassaralla, Jr.; Bevacizumab Intravitreal Injection for Myopic Choroidal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2009;50(13):2273.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To evaluate the clinical results of bevacizumab intravitreal injection (BII) in choroidal neovascularization (CNV) secondary to pathologic myopia (PM-CNV).

Methods: : 30 patients with subfoveal PM-CNV, were treated with of 1.25 mg BII. ETDRS best corrected visual acuity, macular thickness on OCT scans, and angiographic features were recorded and evaluated. The aspect of OCT scans passing across the PM-CNV was also analyzed. BII were repeated only in case of persistent angiographic leakage and if OCT scans showed retinal thickening or edema and serous retinal detachment. The follow-up period was at least 1 year.

Results: : The mean age of the study patients was 43 years (28-51) and the mean refractive error -14.75 D. At 12 months post-treatment, mean VA increased from 20/100 (20/400 -20/40) to 20/60 (20/200-20/25). Only 2 patients lost 38 letters due to macular atrophy; the other 18 increased or stabilized their VA. Mean macular thickness decreased from 329 to 258 µm. No ocular or general side effects were recorded.

Conclusions: : These short-term results suggest that BII are effective and safe in patients with PM-CNV. The number of patients in this pilot study was limited and the follow-up is too short to make any specific treatment recommendations, but the favorable short-term results suggest further study is needed.

Clinical Trial: : www.clinicaltrials.gov NCT00797992

Keywords: myopia • retinal neovascularization • drug toxicity/drug effects 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.